Basit öğe kaydını göster

dc.contributor.authorDinçel, Efe Doğukan
dc.contributor.authorKuran, Ebru Didem
dc.contributor.authorEce, Abdulilah
dc.contributor.authorBaşoğlu Ünal, Faika
dc.contributor.authorRenzi, Gioele
dc.contributor.authorBadii, Gloria
dc.contributor.authorCarta, Fabrizio
dc.contributor.authorSupuran, Cladiu T.
dc.contributor.authorUlusoy Güzeldemirci, Nuray
dc.date.accessioned2025-06-17T11:27:54Z
dc.date.available2025-06-17T11:27:54Z
dc.date.issued2025en_US
dc.identifier.citationDincel ED, Kuran ED, Ece A, Başoğlu-Ünal F, Renzi G, Badii G, Carta F, Supuran CT, Ulusoy-Güzeldemirci N. Preliminary Investigations on Acyl Hydrazones Bearing Sulfonamides as Inhibitors of the Human Carbonic Anhydrase Isoforms I, II, IX, and XII. Anticancer Agents Med Chem. 2025 Feb 25.en_US
dc.identifier.issn1875-5992
dc.identifier.urihttps://pubmed.ncbi.nlm.nih.gov/40012289/
dc.identifier.urihttps://www.benthamscience.com/journal/1
dc.identifier.urihttps://hdl.handle.net/20.500.12780/1155
dc.description.abstractAim: The present study aims to identify the synthesis and structural characterization of acyl hydrazone- sulfonamide-containing compounds that were tested in vitro on human carbonic anhydrase (hCA) isoforms I, II, IX, and XII. Methods: Herein, acyl hydrazone derivatives containing the primary sulfonamide moiety were synthesized via a three-step synthetic pathway starting from the commercially available 4-sulfamoyl benzoic acid. Structural characterizations of the final compounds were assessed through IR IR, 1H-NMR, 13C-NMR, and elemental analyses. The in vitro profiling activity of the final compounds on the Carbonic Anhydrases (CAs; EC 4.2.1.1) I, II, IX, and XII were performed by means of the stopped-flow technique and revealed nanomolar inhibitory potencies on the selected targets. Molecular docking and molecular dynamic simulations afforded a detailed understanding of the binding modes of the most effective compounds. Results: We reported the synthesis and structural characterization of 25 acyl hydrazone-sulfonamide-containing compounds that were tested in vitro on the hCAs I, II, IX, and XII isoforms for their inhibitory features. Overall, all compounds showed nanomolar inhibition potencies on the panel of hCAs considered, and their binding modes were deciphered by means of in-silico studies. Molecular docking followed by MD simulations confirmed the stability of 4l-hCA I, 4n-hCA II, 4t-hCA II, 4v-hCA XII, and 4w-hCA XII complexes. Conclusion: This study presents a deep understanding of the structural determinants influencing the affinity and selectivity of the designed compounds towards different hCAs, thus offering valuable insights for further optimization and development in the field.en_US
dc.language.isoengen_US
dc.publisherBentham Scienceen_US
dc.relation.isversionof10.2174/0118715206356980250113074705en_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectSynthesisen_US
dc.subjectAcyl hydrazonesen_US
dc.subjectCarbonic Anhydraseen_US
dc.subjectMolecular dynamic simulationsen_US
dc.titlePreliminary investigations on acyl hydrazones bearing sulfonamides as inhibitors of the human Carbonic Anhydrase isoforms I, II, IX, and XIIen_US
dc.typearticleen_US
dc.contributor.departmentİstanbul Kent Üniversitesi, Fakülteler, Eczacılık Fakültesi, Eczacılık Meslek Bilimleri Bölümüen_US
dc.contributor.authorID0000-0001-5068-0188en_US
dc.contributor.institutionauthorKuran, Ebru Didem
dc.relation.journalAnti-Cancer Agents in Medicinal Chemistryen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US


Bu öğenin dosyaları:

DosyalarBoyutBiçimGöster

Bu öğe ile ilişkili dosya yok.

Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.

Basit öğe kaydını göster